


Please acknowledge receipt of the following by affixing hereon the Patent and Trademark Office date stamp and returning this card to our office.

Applicant: Mueller et al.
Serial No.: 09/186,341
For: COMPOUNDS ACTIVE AT A NOVEL SITE ON
RECEPTOR-OPERATED CALCIUM CHANNELS
USEFUL FOR TREATMENT OF
NEUROLOGICAL DISORDERS AND DISEASES
Filed: November 4, 1998
Attorney(s): Sheryl R. Silverstein
Docket No.: 238/105 US
Date of Deposit: August 13, 1999
Enclosure(s): Information Disclosure Statement, PTO Form 1449,
copy of application Serial No. 08/763,480 and postcard

Please acknowledge receipt of the following by affixing hereon the Patent and Trademark Office date stamp and returning this card to our office.

Applicant: Mueller et al.
Serial No.: 09/186,341
For: COMPOUNDS ACTIVE AT A NOVEL SITE ON
RECEPTOR-OPERATED CALCIUM CHANNELS
USEFUL FOR TREATMENT OF
NEUROLOGICAL DISORDERS AND DISEASES
Filed: November 4, 1998
Attorney(s): Sheryl R. Silverstein
Docket No.: 238/105 US
Date of Deposit: August 13, 1999
Enclosure(s): Information Disclosure Statement, PTO Form 1449,
copy of application Serial No. 08/763,480 and postcard



NPS

IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

In re the Application of:

Mueller et al.

Serial No.: 09/186,341

Filed: November 4, 1998

For: COMPOUNDS ACTIVE AT A
NOVEL SITE ON RECEPTOR-
OPERATED CALCIUM CHANNELS
USEFUL FOR TREATMENT OF
NEUROLOGICAL DISORDERS
AND DISEASES

)
) Group Art Unit: 1611

)
) Examiner: Raymond, R.

INFORMATION DISCLOSURE STATEMENT

Assistant Commissioner for Patents
Washington, D.C. 20231

Sir:

Enclosed is Form PTO-1449 listing a patent which has recently received a Notice of Allowance. A copy of the U.S. patent application is submitted herewith. USSN 08/763,480 is a parent application to the above-referenced application.

SD-125936.1

CERTIFICATE OF MAILING
(37 C.F.R. §1.8a)

I hereby certify that this paper (along with any referred to as being attached or enclosed) is being deposited with the United States Postal Service on the date shown below with sufficient postage as First Class Mail in an envelope addressed to the Assistant Commissioner for Patents, Washington, D.C. 20231.

8/13/99
Date of Deposit

Diana Neuner

Name of Person Mailing Paper

Diana Neuner

Signature of Person Mailing Paper

At this time, no fee is believed due in connection with this Information Disclosure Statement,
however, please charge Deposit Account No. 12-2475 for any deficiencies.

Respectfully submitted,

LYON & LYON LLP

Dated: August 13, 1999

By: Sheryl R. Silverstein
Sheryl R. Silverstein
Reg. No. 40,812

633 West Fifth Street, Suite 4700
Los Angeles, California 90071-2066
Phone: (858) 552-8400
Fax: (213) 955-0440

IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

Applicant: Alan L. Mueller, et al.

Title: COMPOUNDS ACTIVE AT A
NOVEL SITE ON RECEPTOR-
OPERATED CALCIUM
CHANNELS USEFUL FOR
TREATMENT OF
NEUROLOGICAL DISORDERS
AND DISEASES

Appl. No.: 09/825,373

Filing Date: 04/02/2001

Examiner: R. Raymond

Art Unit: 1624

<p>CERTIFICATE OF MAILING</p> <p>I hereby certify that this correspondence is being deposited with the United States Postal Service with sufficient postage as First Class Mail in an envelope addressed to: Commissioner for Patents, PO Box 1450, Alexandria, Virginia 22313-1450, on the date below.</p> <p><u>DIANE GARCIA</u> (Printed Name)</p> <p><u><i>Diane Garcia</i></u> (Signature)</p> <p><u>10-15-03</u> (Date of Deposit)</p>

SUPPLEMENTAL INFORMATION DISCLOSURE STATEMENT
UNDER 37 CFR §1.56

Commissioner for Patents
PO Box 1450
Alexandria, Virginia 22313-1450

Sir:

Submitted herewith on Form PTO/SB/08 is a listing of documents known to Applicants in order to comply with Applicants' duty of disclosure pursuant to 37 CFR §1.56. A copy of each listed document is being submitted to comply with the provisions of 37 CFR §1.97 and §1.98.

The submission of any document herewith, which is not a statutory bar, is not intended as an admission that such document constitutes prior art against the claims of the present application or that such document is considered material to patentability as defined in 37 CFR §1.56(b). Applicants do not waive any rights to take any action which would be appropriate to antedate or otherwise remove as a competent reference any document which is determined to be a *prima facie* art reference against the claims of the present application.

TIMING OF THE DISCLOSURE

The listed documents are being submitted in compliance with 37 CFR §1.97(c), before the mailing date of either a final action under 37 CFR §1.113, a notice of allowance under 37 CFR §1.113, or an action that otherwise closes prosecution in the application.

RELEVANCE OF EACH DOCUMENT

All of the documents are in English.

Applicants respectfully request that any listed document be considered by the Examiner and be made of record in the present application and that an initialed copy of Form PTO/SB/08 be returned in accordance with MPEP §609.

FEE

A fee in connection with submission of a supplemental information disclosure statement under 37 CFR §1.97(c) in the amount of \$180.00 in accordance with 37 CFR §1.17(p) is attached.

The Commissioner is hereby authorized to charge any additional fees which may be required regarding this application under 37 CFR §§ 1.16-1.17, or credit any overpayment, to Deposit Account No. 50-0872. Should no proper payment be enclosed herewith, as by a check being in the wrong amount, unsigned, post-dated, otherwise improper or informal or even entirely missing, the Commissioner is authorized to charge the unpaid amount to Deposit Account No. 50-0872.

Respectfully submitted,

Date Oct. 14, 2003

By Richard San Pietro

FOLEY & LARDNER

Customer Number: 33588

Telephone: (858) 847-6717

Facsimile: (858) 792-6773

Richard San Pietro

Attorney for Applicant

Registration No. 45,071

Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it contains a valid OMB control number.

Substitute for form 1449B/PTO INFORMATION DISCLOSURE STATEMENT BY APPLICANT <i>(use as many sheets as necessary)</i>				Complete if Known	
				Application Number	09/825,373
				Filing Date	04/02/2001
				First Named Inventor	ALAN L. MUELLER
				Group Art Unit	1624
				Examiner Name	R. Raymond
Sheet	1	of	1	Attorney Docket Number	072827-0336

U.S. PATENT DOCUMENTS

Examiner Initials*	Cite No. ¹	U.S. Patent Document		Name of Patentee or Applicant of Cited Document	Date of Publication of Cited Document MM-DD-YYYY	Pages, Columns, Lines, Where Relevant Passages or Relevant Figures Appear
		Number	Kind Code ² (if known)			

FOREIGN PATENT DOCUMENTS

Examiner Initials*	Cite No. ¹	Foreign Patent Document			Name of Patentee or Applicant of Cited Documents	Date of Publication of Cited Document MM-DD-YYYY	Pages, Columns, Lines, Where Relevant Passages or Relevant Figures Appear	T ⁶
		Office ³	Number ⁴	Kind Code ⁵ (if known)				
	A1	WO	95/21612		NPS Pharmaceuticals, Inc.	08-17-1995		
	A2	AU	723349		NPS Pharmaceuticals, Inc.	01-05-1998		

NON PATENT LITERATURE DOCUMENTS

Examiner Initials*	Cite No. ¹	Include name of the author (in CAPITAL LETTERS), title of the article (when appropriate), title of the item (book, magazine, journal, serial, symposium, catalog, etc.) date, page(s), volume-issue number(s), publisher, city and/or country where published.	T ⁶

Examiner Signature	Date Considered	
--------------------	-----------------	--

*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

¹ Unique citation designation number. ² See attached Kinds of U.S. Patent Documents. ³ Enter Office that issued the document, by the two-letter code (WIPO Standard ST.3). ⁴ For Japanese patent documents, the indication of the year of the reign of the Emperor must precede the serial number of the patent document. ⁵ Kind of document by the appropriate symbols as indicated on the document under WIPO Standard ST. 16 if possible. ⁶ Applicant is to place a check mark here if English language Translation is attached.

Burden Hour Statement: This form is estimated to take 2.0 hours to complete. Time will vary depending upon the needs of the individual case. Any comments on the amount of time you are required to complete this form should be sent to the Chief Information Officer, U.S. Patent and Trademark Office, PO Box 1450, Alexandria, Virginia 22313-1450. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Commissioner for Patents, PO Box 1450, Alexandria, Virginia 22313-1450.

Please acknowledge receipt of the following by affixing hereon the Patent and Trademark Office date stamp and returning this card to our office.

Applicant: Alan Li Mueller et al.
Serial No.: 09/186,341
For: **COMPOUNDS ACTIVE AT A NOVEL SITE ON RECEPTOR-
OPERATED CALCIUM CHANNELS USEFUL FOR
TREATMENT OF NEUROLOGICAL DISORDERS AND
DISEASES**
Filed: November 4, 1998

Attorney(s): S. Silverstein
Docket No.: 238/105
Date of Deposit: 2/5/99

Enclosure(s): INFORMATION DISCLOSURE STATEMENT, FORM 1449 AND
REPLY POSTCARD

SRS:kmc

NPS

IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

In re the Application of:

Alan L. Mueller et al.

Serial No.: 09/186,341

Filed: November 4, 1998

For: COMPOUNDS ACTIVE AT A NOVEL SITE
ON RECEPTOR-OPERATED CALCIUM
CHANNELS USEFUL FOR TREATMENT
OF NEUROLOGICAL DISORDERS AND
DISEASES

)
) Group Art Unit: 1621

)
) Examiner: To be assigned
)
)
)
)
)
)

INFORMATION DISCLOSURE STATEMENT

Assistant Commissioner for Patents
Washington, D.C. 20231

Sir:

In compliance with the Applicants' duty under 37 CFR 1.97-98, the following information is brought to the attention of the Examiner. Copies of items listed on the attached Form PTO-1449 were cited and/or provided in parent application number 08/873,011 filed June 11, 1997.

The items identified in this Information Disclosure Statement may or may not be "material" pursuant to 37 CFR 1.56 and the submission thereof by Applicants shall not be construed as an admission that any such patent, publication or other information referred to therein is material or

SD-103078.1

CERTIFICATE OF MAILING
(37 C.F.R. §1.8a)

I hereby certify that this paper (along with any referred to as being attached or enclosed) is being deposited with the United States Postal Service on the date shown below with sufficient postage as First Class Mail in an envelope addressed to the Assistant Commissioner for Patents, Washington, D.C. 20231.

February 5, 1999

Date of Deposit

Karen M. Cruz

Name of Person Mailing Paper


Signature of Person Mailing Paper

considered to be material (37 CFR 1.97(h)), or even qualifies as "prior art" under 35 U.S.C. § 102 with respect to this invention unless specifically designated by Applicants as such.

The filing of this Information Disclosure Statement shall not be construed to mean that a search has been made or that no other material information, as defined in 37 CFR 1.56, exists.

This Information Disclosure Statement is believed to be timely in that it is being submitted under 37 CFR 1.97(b) (3) before the mailing of a first Office Action on the merits, whereby no petition or fee is required. However, if counsel for Applicant is in error in this regard, the Commissioner is requested to consider this a petition and he is authorized to charge any required petition fee to counsel's Deposit Account No. 12-2475.

Respectfully submitted,

LYON & LYON LLP

Dated: February 4, 1999

By: Sheryl R. Silverstein
Sheryl R. Silverstein
Reg. No. 40,812

633 West Fifth Street, Suite 4700
Los Angeles, California 90071-2066
(213) 489-1600

FORM PTO-1449 LIST OF PATENTS AND OTHER ITEMS FOR APPLICANT'S INFORMATION DISCLOSURE STATEMENT (Use several sheets if necessary)	A. Y. DOCKET NO. 238/105	SERIAL NO. 09/186,341
	APPLICANT: Alan L. Mueller et al.	
	FILING DATE: November 4, 1998	GROUP: 1621

U.S. PATENT DOCUMENTS							
EXAMINER INITIAL		DOCUMENT NUMBER	DATE	NAME	CLASS	SUB CLASS	FILING DATE
	AA	3,258,488	6/28/66	Judd et al.	260	570.8	8/12/63
	AB	3,372,193	3/5/68	Moffet et al.	564	375	
	AC	4,018,895	4/19/77	Molloy et al.	514	649	
	AD	4,070,373	1/1978	Winter et al.	549	354	
	AE	4,313,896	2/2/82	Molloy et al.	562	597	
	AF	5,037,846	8/6/91	Saccomano et al.	514	419	
	AG	5,145,870	9/8/92	Jakobsen et al.	514	524	
	AH	5,185,369	2/9/93	Saccomano et al.	514	502	
	AI	5,310,756	5/10/94	Jakobsen et al.	514	524	
	AJ	5,574,173	11/1996	Ting et al.	549	353	

FOREIGN PATENT DOCUMENTS									
EXAMINER INITIAL		DOCUMENT NUMBER	DATE	COUNTRY	CLASS	SUB CLASS	TRANSLATION		
							YES	NO	
	AK	1 051 281	25.02.59	DE					
	AL	33 285	05.12.64	DE (Klosa et al.)					
	AM	1 169 944	11.07.67	GB (Jones)					
	AN	1 129 029	02.10.68	GB (Boehringer)					
	AO	1 129 210	02.10.68	GB (Boehringer)					
	AP	1,134,715	27.11.68	GB (Maisey)					
	AQ	1,135,926	11.12.68	GB (Maisey)					
	AR	1 793 735	25.07.73	DE (Winter et al.)					
	AS	17 93 735	26.07.73	DE (Boehringer Mannheim)					
	AT	300,541	25.06.74	Netherlands					
	AU	23 35 943	30.01.75	DE (Boehringer Mannheim)					
	AV	2 277 589	06.02.76	FR (Boehringer)					
	AW	0 005 658	25.04.79	EP (Leconte et al.)					
	AX	0 208 523	14.01.87	EP (Usherwood et al.)					
	AY	0 399 504	23.05.90	EP (Jakobsen et al.)					
	AZ	0 436 332	10.07.91	EP (Saccomano et al.)					
	BA	92/14709	03.09.92	WO/PCT (Goldin et al.)					

EXAMINER:

DATE CONSIDERED:

EXAMINER: Initial if reference is considered, whether or not citation is in conformance with MPEP 609; Draw line through citation if not in conformance and not considered. Include a copy of this form with next communication to applicant.

FORM PTO-1449 LIST OF PATENTS AND OTHER ITEMS FOR APPLICANT'S INFORMATION DISCLOSURE STATEMENT (Use several sheets if necessary)	A. Y. DOCKET NO. 238/105	SERIAL NO. 09/186,341
	APPLICANT: Alan L. Mueller et al.	
	FILING DATE: November 4, 1998	GROUP: 1621

FOREIGN PATENT DOCUMENTS								
EXAMINER INITIAL		DOCUMENT NUMBER	DATE	COUNTRY	CLASS	SUB CLASS	TRANSLATION	
							YES	NO
	BB	93/04036	04.03.93	WO/PCT (Saccomano et al.)				
	BC	93/04041	04.03.93	WO/PCT (Saccomano et al.)				
	BD	93/04373	04.03.93	WO/PCT (Nemeth et al.)				
	BE	4 239 816	01.06.94	DE (Keller et al.)				
	BF	95/15959	15.06.95	WO/PCT (Schering Corp.)				
	BG	95/21612	17.08.95	WO/PCT (NPS)				
	BH	96/05818	29.02.96	WO/PCT (Fuller et al.)				
	BI	96/40097	19.12.96	WO/PCT (Mueller et al.)				
	BJ	97/46511	11.12.97	WO/PCT (Vanwagenen)				

OTHER DOCUMENTS (Including Author, Title, Date, Pertinent Pages, Etc.)		
BK	Akaike et al., "Spider Toxin Blocks Excitatory Amino Acid Responses in Isolated Hippocampal Pyramidal Neurons," <u>Neuroscience Letters</u> 79:326-330 (1987)	
BL	Anis et al., "Structure-Activity Relationships of Philanthotoxin Analogs and Polyamines on N-Methyl-D-Aspartate and Nicotinic Acetylcholine Receptors," <u>Journal of Pharmacology and Experimental Therapeutics</u> 254:764-773 (1990)	
BM	Artman et al., "Preferential Inhibitory Effects of Arylamine Spider Toxins on NMDA Receptor-Mediated Increases in Cytosolic Calcium," <u>Society for Neuroscience Abstracts</u> 17(Part 1):394 at abstract no. 163.19 (1991)	
BN	Ashe et al., "Argiotoxin-636 Blocks Excitatory Synaptic Transmission in Rat Hippocampal CA1 Pyramidal Neurons," <u>Brain Research</u> 480:234-240 (1989)	
BO	Banciu et al., "Carbonium ion reactions. XII. Acetolysis of 5-(2-bromoethyl)-5H-dibenzol [a,d] cycloheptene and nitrous acid deamination of 5-(2-aminoethyl)-5H-dibenzo [a,d] cycloheptene," <u>Revue Roumaine de Chimie</u> 20(1):121-127 (1975)	
BP	Banciu et al., <u>Chemical Abstracts</u> , Vol. 83 Abstract 146868 (1975)	
BQ	Beckett and Casy, "Configurational Studies in Synthetic Analgesics," <u>Journal of the Chemical Society</u> pp.900-904 (February 1955)	
BR	Blagbrough and Usherwood, "Polyamine amide toxins as pharmacological tools and pharmaceutical agents," <u>Proceedings of the Royal Society of Edinburgh</u> 99B(1-2):67-81 (1992)	
BS	Blagbrough et al., "Arthropod Toxins as Leads for Novel Insecticides: An Assessment of Polyamine Amides as Glutamate Antagonists," <u>Toxicon</u> 30:303-322 (1992)	
BT	Blake et al., "2-Methyl-3,3-Diphenyl-3-Propanolamine (2-MDP) Selectively Antagonises N-Methyl-Aspartate (NMA)," <u>Pharmacology Biochemistry & Behavior</u> 24:23-25 (1986)	
BU	Blaschke et al., "A Single Amino Acid Determines the Subunit-Specific Spider Toxin Block of Amino-3-Hydroxy-5-Methylisoxazole-4-Propionate/Kainate Receptor Channels," <u>Proc. Natl. Acad. Sci. USA</u> 90:6528-6532 (1993)	
BV	Boehringer et al., <u>Chemical Abstracts</u> , Vol. 70 Abstract 37664 (1969)	
BW	Boehringer Mannheim, <u>Chemical Abstracts</u> , Vol. 86 Abstract 16562 (1977)	

EXAMINER:	DATE CONSIDERED:
EXAMINER: Initial if reference is considered, whether or not citation is in conformance with MPEP 609; Draw line through citation if not in conformance and not considered. Include a copy of this form with next communication to applicant.	

FORM PTO-1449 LIST OF PATENTS AND OTHER ITEMS FOR APPLICANT'S INFORMATION DISCLOSURE STATEMENT (Use several sheets if necessary)	A. IY. DOCKET NO. 238/105	SERIAL NO. 09/186,341
	APPLICANT: Alan L. Mueller et al.	
	FILING DATE: November 4, 1998	GROUP: 1621

OTHER DOCUMENTS (Including Author, Title, Date, Pertinent Pages, Etc.)		
BX	Brackley et al., "Selective Antagonism of Native and Cloned Kainate and NMDA Receptors by Polyamine-Containing Toxins," <u>Journal of Pharmacology and Experimental Therapeutics</u> 266:1573-1580 (1993)	
BY	Bruce et al., "Structure-Activity Relationships of Analogues of The WASP Toxin Philanthotoxin: Non-Competitive Antagonists of Quisqualate Receptors," <u>Toxicon</u> 28(11):1333-1346 (1990)	
BZ	Burtsev and Savkov, "Calcium Antagonists (Finoptin and Senzit) in the Treatment of Cerebrovascular Disorders," <u>Klinicheskaja Meditsina</u> 67(9):51-54 (1989) (abstract from MEDLINE)	
CA	Buschauer et al., "Synthesis and histamine H ₂ agonistic activity of arpromidine analogues: replacement of the pheniramine-like moiety by non-heterocyclic groups," <u>Eur. J. Med. Chem.</u> 27:321-330 (1992)	
CB	Camps et al., "A New and Efficient One-Pot Preparation of Alkyl Halides From Alcohols," <u>Synthesis Communications</u> pp. 511-512 (May 1987)	
CC	<u>Chemical Abstracts</u> 5:423 (1959)	
CD	<u>Chemical Abstracts</u> 54:24555-24556 (1960)	
CE	<u>Chemical Abstracts</u> 54:424a (1960)	
CF	<u>Chemical Abstracts</u> 66:4375 (1967)	
CG	<u>Chemical Abstracts</u> 67:3059 (1967)	
CH	<u>Chemical Abstracts</u> 69:3322 (1968)	
CI	Chemical Abstracts Service, Registry Handbook, Reg. No. 114272-62-7 through 116231-28-8, 1988 Supplement	
CJ	Cheng and Prusoff, "Relationship Between the Inhibition Constant (K _i) and the Concentration of Inhibitor Which Causes 50 Per Cent Inhibition (I ₅₀) of an Enzymatic Reaction," <u>Biochemical Pharmacology</u> 22:3099-3108 (1973)	
CK	Choi et al., "Glutamate Neurotoxicity in Cortical Cell Culture," <u>J. Neuroscience</u> 7:357-368 (1987)	
CL	Choi et al., "Synthesis and Assay of Hybrid Analogs of Argiotoxin-636 and Philanthotoxin-433: Glutamate Receptor Antagonists," <u>Tetrahedron</u> 49:5777-5790 (1993)	
CM	Choi, "Glutamate Neurotoxicity and Diseases of the Nervous System," <u>Neuron</u> 1:623-634 (1988)	
CN	Collingridge and Davis, "Ch. 9 - NMDA receptors and long-term potentiation in the hippocampus," in <u>The NMDA Receptor</u> , edited by Watkins and Collingridge, IRL Press, p. 123-135 (1989)	
CO	Cramer et al., "Kainic Acid and 4-Aminopyridine Seizure Models in Mice: Evaluation of Efficacy of Anti-Epileptic Agents and Calcium Antagonists," <u>Life Sciences</u> 54:PL271-PL275 (1994)	
CP	Davies et al., "Polyamine Spider Toxins Are Potent Un-competitive Antagonists of Rat Cortex Excitatory Amino Acid Receptors," <u>European Journal of Pharmacology - Molecular Pharmacology Section</u> 227:51-56 (1992)	
CQ	Deneris et al., "Pharmacological and Functional Diversity of Neuronal Nicotinic Acetylcholine Receptors," <u>TIPS</u> 12:34-40 (1991)	
CR	Dickenson, "A Cure for Wind-Up: NMDA Receptor Antagonists as Potential Analgesics," <u>TIPS</u> 11:307-309 (1990)	
CS	Dingledine et al., "Excitatory Amino Acid Receptors in Epilepsy," <u>TIPS</u> 11:334-338 (1990)	
CT	Donevan and Rogawski, "GYKI 52466, a 2,3-Benzodiazepine, is a Highly Selective, Noncompetitive Antagonist of AMPA/Kainate Receptor Responses," <u>Neuron</u> 10:51-59 (1993)	

EXAMINER:	DATE CONSIDERED:
EXAMINER: Initial if reference is considered, whether or not citation is in conformance with MPEP 609; Draw line through citation if not in conformance and not considered. Include a copy of this form with next communication to applicant.	

FORM PTO-1449 LIST OF PATENTS AND OTHER ITEMS FOR APPLICANT'S INFORMATION DISCLOSURE STATEMENT (Use several sheets if necessary)	A. Y. DOCKET NO. 238/105	SERIAL NO. 09/186,341
	APPLICANT: Alan L. Mueller et al.	
	FILING DATE: November 4, 1998	GROUP: 1621

OTHER DOCUMENTS (Including Author, Title, Date, Pertinent Pages, Etc.)		
	CU	Donevan et al., "Arcaine Blocks N-Methyl-D-Aspartate Receptor Responses by an Open Channel Mechanism: Whole-Cell and Single-Channel Recording Studies in Cultured Hippocampal Neurons," <u>Molecular Pharmacology</u> 41:727-735 (1992)
	CV	Draguhn et al., "Argiotoxin ₆₃₆ inhibits NMDA-activated ion channels expressed in <i>Xenopus</i> oocytes," <u>Neuroscience Letters</u> 132:187-190 (1991)
	CW	Fingl and Woodbury, "Chapter 1 - General Principles," in <u>The Pharmacological Basis of Therapeutics</u> 5th edition, Goodman and Gilman editors, MacMillan Publishing Co., Inc., New York, pp. 1-46 (1975)
	CX	Fisher and Bogousslavsky, "Evolving Toward Effective Therapy for Acute Ischemic Stroke," <u>JAMA</u> 270:360-364 (1993)
	CY	Foye et al., <u>Principals of Medicinal Chemistry</u> , 4th edition, Lea & Febiger/Williams and Wilkins, Philadelphia, PA, pp. 233, 265, 281-282, 340-341, 418-427 and 430 (1995)
	CZ	Ginsberg and Busto, "Rodent Models of Cerebral Ischemia," <u>Stroke</u> 20:1627-1642 (1989)
	DA	Gisvold and Steen, "Drug Therapy in Brain Ischaemia," <u>Br. J. Anaesth.</u> 57:96-109 (1985)
	DB	Grishin et al., "Isolation and Structure Analysis of Components from Venom of the Spider <i>Argiope Lobata</i> ," <u>Toxicon</u> 27:451-549 (1989)
	DC	Gullak et al., "CNS Binding Sites of the Novel NMDA Antagonist Arg-636," <u>Soc. Neurosci. Abst.</u> 15:1168 at abstract no. 463.23 (1989)
	DD	Hayes et al., "Anticonvulsant Properties of Phencyclidine-Like Drugs in Mice," <u>European Journal of Pharmacology</u> 117:121-125 (1985)
	DE	Helke and Raines, "Antitensor Effects of 3,3-Diphenyl-n-Propylamine in the Mouse," <u>European Journal of Pharmacology</u> 48:231-235 (1978)
	DF	Herlitze et al., "Argiotoxin Detects Molecular Differences in AMPA Receptor Channels," <u>Neuron</u> 10:1131-1140 (1993)
	DG	Herold and Yaksh, "Anesthesia and Muscle Relaxation with Intrathecal Injections of AR636 and AG489, Two Acylpolyamine Spider Toxins, in Rat," <u>Anesthesiology</u> 77:507-512 (1992)
	DH	Hill, "A New Mathematical Treatment of Changes of Ionic Concentration in Muscle and Nerve Under the Action of Electric Currents, with a Theory as to Their Mode of Excitation," <u>Journal of Physiology</u> 40:190-224 (1910)
	DI	Honoré et al., "Quinoxalinediones: Potent Competitive Non-NMDA Glutamate Receptor Antagonists," <u>Science</u> 241:701-703 (1988)
	DJ	Hughes, "Merz' Novel Approach to the Treatment of Dementia," <u>Script No.</u> 1666:24-25 (1991)
	DK	Jackson and Parks, "Spider Toxins: Recent Applications In Neurobiology," <u>Ann. Rev. Neurosci.</u> 12:405-414 (1989)
	DL	Jackson and Usherwood, "Spider Toxins as Tools for Dissecting Elements of Excitatory Amino Acid Transmission," <u>TINS</u> 11:278-283 (1988)
	DM	Janssen et al., <u>Synthetic Analgesics: Part I - Diphenylpropylamines</u> , Pergamon Press, pp. 1-109 (1960)
	DN	Jasys et al., "Isolation, Structure Elucidation, and Synthesis of Novel Hydroxylamine-Containing Polyamines From the Venom of the <i>Agelenopsis Aperta</i> Spider," <u>J. Amer. Chem. Soc.</u> 112:6696-6704 (1990)
	DO	Jasys et al., "The Total Synthesis of Argiotoxins 636, 659 and 673," <u>Tetrahedron Letters</u> 29:6223-6226 (1988)
	DP	Jones and Lodge, "Comparison of Some Arthropod Toxins and Toxin Fragments as Antagonists of Excitatory Amino Acid-Induced Excitation of Rat Spinal Neurones," <u>European Journal of Pharmacology</u> 204:203-209 (1991)

EXAMINER:	DATE CONSIDERED:
EXAMINER: Initial if reference is considered, whether or not citation is in conformance with MPEP 609; Draw line through citation if not in conformance and not considered. Include a copy of this form with next communication to applicant.	

FORM PTO-1449 LIST OF PATENTS AND OTHER ITEMS FOR APPLICANT'S INFORMATION DISCLOSURE STATEMENT (Use several sheets if necessary)	A. I. Y. DOCKET NO. 238/105	SERIAL NO. 09/186,341
	APPLICANT: Alan L. Mueller et al.	
	FILING DATE: November 4, 1998	GROUP: 1621

OTHER DOCUMENTS (Including Author, Title, Date, Pertinent Pages, Etc.)		
	DQ	Jones et al., "Philanthotoxin Blocks Quisqualate-, AMPA- and Kainate-, but not NMDA-, Induced Excitation of Rat Brainstem Neurones <i>in vivo</i> ," <u>Br. J. Pharmacol.</u> 101:968-970 (1990)
	DR	Jones et al., "Substituted 1,1-Diphenyl-3-aminoprop-1-enes and 1,1-Diphenyl-3-aminopropanes as Potential Antidepressant Agents," <u>J. Med. Chem.</u> 14(2):161-164 (1971)
	DS	Kalman et al., "Difenil-propil-amin-szarmazekok," <u>Magyar Kemiai Folyirat</u> 78:46-49 (1972)
	DT	Kanai et al., "An Analogue of Joro Spider Toxin Selectively Suppresses Hippocampal Epileptic Discharges Induced by Quisqualate," <u>Brain Research</u> 581:161-164 (1992)
	DU	Karpiak et al., "Animal Models for the Study of Drugs in Ischemic Stroke," <u>Annu. Rev. Pharmacol. Toxicol.</u> 29:403-414 (1989)
	DV	Kawai et al., "Effect of a Spider Toxin on Glutaminergic Synapses in the Mammalian Brain," <u>Biomedical Research</u> 3:353-355 (1982)
	DW	Kawai et al., "Spider Toxin and the Glutamate Receptors," <u>Comp. Biochem. Physiol.</u> 98C:87-95 (1991)
	DX	Kawai, "Neuroactive Toxins of Spider Venoms," <u>J. Toxicol. - Toxin Reviews</u> 10:131-167 (1991)
	DY	Keasling and Moffett, "Central Nervous System Agents. 3. Structure-Activity -- Relationship of a Series of Diphenylaminopropanols," <u>Journal of Medicinal Chemistry</u> 14(11):1106-1111 (1971)
	DZ	Kiskin et al., "A Highly Potent and Selective N-Methyl-D-Aspartate Receptor Antagonist From the Venom of the <i>Agelenopsis Aperta</i> Spider," <u>Neuroscience</u> 51:11-18 (1992)
	EA	Kiskin et al., "Argiopine, Argiopines and Pseudoargiopines as Glutamate Receptor Blockers in Hippocampal Neurons," <u>Neurophysiology</u> 21:748-754 (1989) (in Russian)
	EB	Kovacs and Hesse, "Synthetic Analogues of Naturally Occurring Spider Toxins," <u>Helvetica Chimica Acta</u> 75:1909-1924 (1992)
	EC	Kurokawa et al., "Synthesis and Biological Activity of 11-[4-(Cinnamyl)-1-piperazinyl]-1-piperazinyl]-6,11-dihydrodibenz[b,e]oxepin Derivatives, Potential Agents for the Treatment of Cerebrovascular Disorders," <u>Chem. Pharm. Bull.</u> 39(10):2564-2573 (1991)
	ED	Leszkovszky et al., "The Pharmacology of Diphenylalkyl Derivatives," <u>Acta Physiologica Academiae Scientiarum Hungaricae Tomus</u> 29(3-4):283-298 (1966)
	EE	Marcusson et al., "Inhibition of [³ H]paroxetine binding by various serotonin uptake inhibitors: structure-activity relationships," <u>Europ. J. Pharmacol.</u> 215:191-198 (1992)
	EF	McQuaid et al., "Inhibition of [³ H]-MK801 Binding and Protection Against NMDA-Induced Lethality in Mice by a Series of Imipramine Analogs," <u>Research Communications in Chemical Pathology and Pharmacology</u> 77(2):171-178 (1992)
	EG	Meldrum and Garthwaite, "Excitatory Amino Acid Neurotoxicity and Neurodegenerative Disease," <u>TIPS</u> 11:379-387 (1990)
	EH	Meldrum, "Excitatory Amino Acid Neurotransmission in Epilepsy and Anticonvulsant Therapy," in <u>Excitatory Amino Acids</u> , Meldrum et al. editors, New York, Raven Press, pp. 655-670 (1991)
	EI	Melloni et al., "Potential antidepressant agents. Aryloxy-benzyl derivatives of ethanolamine and morpholine," <u>Eur. J. Med. Chem. - Chim. Ther.</u> 19:235-242 (1984)
	EJ	Merck Index, 11th edition, Merck & Co., Inc., Rahway, New Jersey, page 218 at no. 1433, page 337 at no. 2180, page 623 at no. 3916, page 655 at no. 4112, page 1148 at no. 7198, page 1227 at no. 7744, page 1444 at no. 9098, and page 1597 at no. 10024 (1989)
	EK	Mikio et al., "Synthesis of Analgesics," <u>Chemical Abstracts</u> volume 83, no. 7, August 18, 1975 at abstract no. XP002016632

EXAMINER:	DATE CONSIDERED:
EXAMINER: Initial if reference is considered, whether or not citation is in conformance with MPEP 609; Draw line through citation if not in conformance and not considered. Include a copy of this form with next communication to applicant.	

FORM PTO-1449 LIST OF PATENTS AND OTHER ITEMS FOR APPLICANT'S INFORMATION DISCLOSURE STATEMENT (Use several sheets if necessary).	A . . . DOCKET NO. 238/105	SERIAL NO. 09/186,341
	APPLICANT: Alan L. Mueller et al.	
	FILING DATE: November 4, 1998	GROUP: 1621

OTHER DOCUMENTS (Including Author, Title, Date, Pertinent Pages, Etc.)		
EL	Moffett et al., "Central Nervous System Agents. 1. Synthesis of Diphenyl- <i>tert</i> -aminopropanols," <u>J. Med. Chem.</u> 14(11):1088-1100 (1971)	
EM	Mueller et al., "Arylamine Spider Toxins Antagonize NMDA Receptor-Mediated Synaptic Transmission in Rat Hippocampal Slices," <u>Synapse</u> 9:244-250 (1991)	
EN	Mueller et al., "Effects of Polyamine Spider Toxins on NMDA Receptor-Mediated Transmission in Rat Hippocampus <i>In Vitro</i> ," <u>Soc. Neurosci. Abst.</u> 15:945 at abstract no. 373.10 (1989)	
EO	Nakanishi et al., "Bioorganic Studies of Transmitter Receptors with Philanthotoxin Analogs," <u>Pure & Applied Chemistry</u> vol. 66, #3 (March 1994)	
EP	Nakanishi, "Molecular Diversity of Glutamate Receptors and Implications for Brain Function," <u>Science</u> 258:597-603 (1992)	
EQ	Nason et al., "Synthesis of Neurotoxic Nephila Spider Venoms: NSTX-3 and JSTX-3," <u>Tetrahedron Letters</u> 30:2337-2340 (1989)	
ER	Nemeth et al., "Arylamines Derived From Spider Venom Are Potent and Selective NMDA Receptor Antagonists in The Mammalian CNS," in <u>Neuroreceptors, Ion Channels and the Brain</u> , Kawai et al., editors, pp. 21-28 (1992)	
ES	Olney et al., "Pathological Changes Induced in Cerebrocortical Neurons by Phencyclidine and Related Drugs," <u>Science</u> 244:1360-1362 (1989)	
ET	Palmer et al., "Anticonvulsant Properties of Calcium Channel Blockers in Mice: <i>N</i> -Methyl-D-, L-Aspartate- and Bay K 8644-Induced Convulsions are Potentially Blocked by the Dihydropyridines," <u>Epilepsia</u> 34:372-380 (1993)	
EU	Parks et al., "Arylamine Toxins From Funnel-Web Spider (<i>Agelenopsis aperta</i>) Venom Antagonize <i>N</i> -Methyl-D-aspartate Receptor Function in Mammalian Brain," <u>J. Biol. Chem.</u> 266:21523-21529 (1991)	
EV	Parks et al., "Polyamine Spider Toxins Block NMDA Receptor-Mediated Increases in Cytosolic Calcium in Cerebellar Granule Neurons," <u>Soc. Neurosci. Abst.</u> 15:1169 at abstract no. 463.25 (1989)	
EW	Paul et al., "Adaptation of the <i>N</i> -Methyl-D-Aspartate Receptor Complex Following Chronic Antidepressant Treatments," <u>J. Pharmacology and Experimental Therapeutics</u> 269:95-102 (1994)	
EX	Peterson, "Studies on a New Spasmolytic Compound 1,1-diphenyl-3-dimethylaminobutene-1 (A29) related to Methadon, and on the Combined Use of this Compound and a Potent Analgesic Ketobemidone," <u>Acta Pharmacol. et toxicol.</u> 7:51-64 (1951)	
EY	Priestley et al., "Antagonism of responses to excitatory amino acids on rat cortical neurones by the spider toxin, argiotoxin ₆₃₆ ," <u>Br. J. Pharmacol.</u> 97:1315-1323 (1989)	
EZ	Prous, <u>The Year's Drug News, Therapeutic Targets</u> , 1995 Edition, Prous Science Publishers, Barcelona, Spain, pp. 13, 55-56, 58-59, 74, 89, 144-145, 152, 296-297 and 317 (1995)	
FA	Quistad et al., "Paralytic and Insecticidal Toxins from the Funnel Web Spider, <i>Hololena Curta</i> ," <u>Toxicon</u> 29:329-336 (1991)	
FB	Raditsch et al., "Subunit-Specific Block of Cloned NMDA Receptors by Argiotoxin ₆₃₆ ," <u>FEBS Letters</u> 324(1):63-66 (1993)	
FC	Ransom and Stec, "Cooperative Modulation of [³ H]MK-801 Binding to the <i>N</i> -Methyl-D-Aspartate Receptor-Ion Channel Complex by L-Glutamate, Glycine and Polyamines," <u>Journal of Neurochemistry</u> 51:830-836 (1988)	
FD	Reist et al., "Sodium Azide in Dimethylformamide for the Preparation of Amino-Sugars," <u>Chemistry and Industry</u> pp. 1794-1795 (October 13, 1962)	

EXAMINER:	DATE CONSIDERED:
EXAMINER: Initial if reference is considered, whether or not citation is in conformance with MPEP 609; Draw line through citation if not in conformance and not considered. Include a copy of this form with next communication to applicant.	

FORM PTO-1445 LIST OF PATENTS AND OTHER ITEMS FOR APPLICANT'S INFORMATION DISCLOSURE STATEMENT (Use several sheets if necessary)	U.S. DOCKET NO. 238/105	SERIAL NO. 09/186.341
	APPLICANT: Alan L. Mueller et al.	
	FILING DATE: November 4, 1998	GROUP: 1621

OTHER DOCUMENTS (Including Author, Title, Date, Pertinent Pages, Etc.)		
FE	Reynolds and Miller, "Ifenprodil is a Novel Type of N-Methyl-D-Aspartate Receptor Antagonist: Interaction with Polyamines," <u>Molecular Pharmacology</u> 36:758-765 (1989)	
FF	Reynolds, "Arcaine is a Competitive Antagonist of the Polyamine Site on the NMDA Receptor," <u>European Journal of Pharmacology</u> 177:215-216 (1990)	
FG	Reynolds, "The Spider Toxin, Argitoxin ₈₃₈ , Binds to a Mg ²⁺ Site on the N-Methyl-D-Aspartate Receptor Complex," <u>Br. Journal of Pharmacology</u> 103(2):1373-1376 (1991)	
FH	Reynolds, <u>Martindale: The Extra Pharmacopoeia</u> , The Pharmaceutical Press, London, pp. 543-544 (1989)	
FI	Rock and MacDonald, "Spermine and Related Polyamines Produce a Voltage-Dependent Reduction of N-Methyl-D-Aspartate Receptor Single-Channel Conductance," <u>Molecular Pharmacology</u> 42:157-164 (1992)	
FJ	Rogawski, "Therapeutic Potential of Excitatory Amino Acid Antagonists: Channel Blockers and 2,3-benzodiazepines," <u>Trends in Pharmacol. Sci.</u> 14:325-331 (1993)	
FK	Rozental et al., "Allosteric Inhibition of Nicotinic Acetylcholine Receptors of Vertebrates and Insects by Philanthotoxin," <u>Journal of Pharmacology and Experimental Therapeutics</u> 249:123-130 (1989)	
FL	Sacaan and Johnson, "Characterization of the Stimulatory and Inhibitory Effects of Polyamines on [³ H]N-(1-[thienyl]cyclohexyl) piperidine Binding to the N-Methyl-D-Aspartate Receptor Ionophore Complex," <u>Molecular Pharmacology</u> 37:572-577 (1990)	
FM	Saccomano et al., "Arylamine NMDA Antagonists From Spider Venom," <u>201st American Chemical Society National Meeting, Abstracts of Papers - Part 1</u> , Atlanta, Georgia, April 14-19 (1991) (Abstract #10)	
FN	Saccomano et al., "Ch. 30 - Polyamine Spider Toxins: Unique Pharmacological Tools," in <u>Annual Reports in Medicinal Chemistry</u> 24:287-293 (1989)	
FO	Saito et al., "Effects of a Spider Toxin (JSTX) on Hippocampal CA1 Neurons in vitro," <u>Brain Research</u> 481:16-24 (1989)	
FP	Saito et al., "Spider Toxin (JSTX) Blocks Glutamate Synapse in Hippocampal Pyramidal Neurons," <u>Brain Research</u> 346:397-399 (1985)	
FQ	Scatchard, "The Attractions of Proteins For Small Molecules and Ions," <u>Annals New York Academy of Sciences</u> 51:660-672 (1949)	
FR	Scatton et al., "NMDA Receptor Antagonists: Treatment for Brain Ischemia," <u>Drug News & Perspectives</u> 4(2):89-95 (1991)	
FS	Scatton, <u>Therapeutic Potential of NMDA receptor antagonists in Ischemic Cerebrovascular Disease in Drug Strategies in the Prevention and Treatment of Stroke</u> , IBC Technical Services Ltd., 1990	
FT	Seymour and Mena, "In Vivo NMDA Antagonist Activity of the Polyamine Spider Venom Component, Argitoxin-636," <u>Soc. Neurosci. Abst.</u> 15:1168 at abstract no. 463.24 (1989)	
FU	Snell and Johnson, "Ch. 13 - Phencyclidine: Behavioral Correlates of NMDA Antagonism," in <u>Excitatory Amino Acids in Health and Disease</u> , D. Lodge editor, John Wiley & Sons, pp. 261-273 (1988)	
FV	Snyder, "Neurotransmitter Receptor Binding and Drug Discovery," <u>J. Med. Chem.</u> 26:1667-1672 (1983)	
FW	Srebnik et al., "Chiral Synthesis via Organoboranes. 18. Selective Reductions. 43. Diisopinocampheylchloroborane as an Excellent Chiral Reducing Reagent for the Synthesis of Halo Alcohols of High Enantiomeric Purity. A Highly Enantioselective Synthesis of Both Optical Isomers of Tomoxetine, Fluoxetine and Nisoxetine," <u>J. Org. Chem.</u> 53(13):2916-2920 (1988)	

EXAMINER:	DATE CONSIDERED:
EXAMINER: Initial if reference is considered, whether or not citation is in conformance with MPEP 609; Draw line through citation if not in conformance and not considered. Include a copy of this form with next communication to applicant.	

FORM PTO-1449 LIST OF PATENTS AND OTHER ITEMS FOR APPLICANT'S INFORMATION DISCLOSURE STATEMENT (Use several sheets if necessary)	A. Y. DOCKET NO. 238/105	SERIAL NO. 09/186,341
	APPLICANT: Alan L. Mueller et al.	
	FILING DATE: November 4, 1998	GROUP: 1621

OTHER DOCUMENTS (Including Author, Title, Date, Pertinent Pages, Etc.)		
	FX	Sutton et al., "Inhibition of voltage-activated Ca ²⁺ currents from cultured sensory neurones by spermine, argiotoxin-636 and a synthetic arginine polyamine," <u>Molecular Neuropharmacology</u> 3:37-43 (1993)
	FY	Tang et al., "Phencyclidine-Like Behavioral Effects of 2-Methyl-3,3-Diphenyl-3-Propanolamine (2-MDP), <u>Pharmacology Biochemistry & Behavior</u> 20:209-213 (1984)
	FZ	Teyler and DiScenna, "Long-Term Potentiation," <u>Annu. Rev. Neurosci.</u> 10:131-161 (1987)
	GA	Titeler, <u>Multiple Dopamine Receptors: Receptor Binding Studies in Dopamine Pharmacology, Volume 1</u> , Marcel Dekker, Inc., New York, pp. 1-173 (1983)
	GB	Tsvetkova et al., "Synthesis of aminoalkylxanthenes and aminothioxanthenes," <u>Khim. Farm. Zh.</u> 3(12):17-20 (1969)
	GC	Usherwood and Blagbrough, "Spider Toxins Affecting Glutamate Receptors: Polyamines in Therapeutic Neurochemistry," <u>Pharmac. Ther.</u> pp. 1-24 (1992)
	GD	von Wolfgang J. Fiedler et al., "66. Synthetische Analoga von niedermolekularen Spinnentoxinen mit Acyl-polyamin-Struktur," <u>Helvetica Chimica Acta</u> 76:1167-1181 (1993)
	GE	von Wolfgang J. Fiedler et al., "98. Synthese von selektiv N-funktionalisierten Polyamin-Derivaten," <u>Helvetica Chimica Acta</u> 76:1511-1519 (1993)
	GF	Watkins et al., <u>The NMDA Receptor</u> , Oxford, IRL Press (1989)
	GG	White et al., "Chemicopharmacological Studies on Antispasmodic Action. XII. Structure-Activity Relationship of Aralkylamines," <u>Chem. Pharm.</u> 6(2):147-154 (1958)
	GH	White et al., "Some Pharmacological Properties of 3:3-Diphenyl-Propanolamines, -Allylamines and -Propylamines," <u>Brit. J. Pharmacol.</u> 6:560-571 (1951)
	GI	Wiley and Balster, "Preclinical Evaluation of N-Methyl-D-Aspartate Antagonists for Antianxiety Effects: A Review," in <u>Multiple Sigma and PCP Receptor Ligands: Mechanisms for Neuromodulation and Neuroprotection?</u> NPP Books, Ann Arbor, Michigan, pp. 801-815 (1992)
	GJ	Willeits et al., "The Behavioral Pharmacology of NMDA Receptor Antagonists," <u>Trends Pharmacol. Sci.</u> 11:423-428 (1990)
	GK	Williams et al., "Characterization of Polyamines Having Agonist, Antagonist, and Inverse Agonist Effects at the Polyamine Recognition Site of the NMDA Receptor," <u>Neuron</u> 5:199-208 (1990)
	GL	Williams et al., "Effects of Polyamines on the Binding of [³ H]MK-801 to the N-Methyl-D-Aspartate Receptor: Pharmacological Evidence for the Existence of a Polyamine Recognition Site," <u>Molecular Pharmacology</u> 36:575-581 (1989)
	GM	Williams, "Effects of <i>Agelenopsis aperta</i> Toxins on the N-Methyl-D-Aspartate Receptor: Polyamine-Like and High-Affinity Antagonist Actions," <u>Journal of Pharmacology and Experimental Therapeutics</u> 266:231-236 (1993)
	GN	Williams, "Ifenprodil Discriminates Subtypes of the N-Methyl-D-Aspartate Receptor: Selectivity and Mechanisms at Recombinant Heteromeric Receptors," <u>Molecular Pharmacology</u> 44:851-859 (1993)
	GO	Yamaguchi et al., "Anticonvulsant Activity of AMPA/Kainate Antagonists: Comparison of GYKI 52466 and NBQX in Maximal Electroshock and Chemoconvulsant Seizure Models," <u>Epilepsy Research</u> 15:179-184 (1993)

EXAMINER:	DATE CONSIDERED:
EXAMINER: Initial if reference is considered, whether or not citation is in conformance with MPEP 609; Draw line through citation if not in conformance and not considered. Include a copy of this form with next communication to applicant.	